Preventing C. difficile infections in high-risk patients
A Pre-emptive Prevention Bundle for Patients at High Risk for Hospital-onset Clostridioides Difficile
This study tests a new approach to prevent C. difficile infections in high-risk patients in hospitals by identifying carriers and using special prevention methods to keep everyone safer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Brigham and Women's Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT05389904 on ClinicalTrials.gov |
What this trial studies
This clinical trial focuses on preventing hospital-onset Clostridioides difficile infections by targeting asymptomatic carriers in ICU and oncology units. It aims to identify these carriers through specific testing and implement a tailored prevention package to stop the progression to active infection and reduce transmission to other patients. The study compares routine care with a preemptive intervention to assess its effectiveness in protecting vulnerable patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients admitted to ICU or oncology units who are identified as carriers of C. difficile.
Not a fit: Patients who are not identified as carriers of C. difficile or those not admitted to ICU or oncology units may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of C. difficile infections in high-risk hospital patients.
How similar studies have performed: Other studies have shown promise in targeting asymptomatic carriers for infection prevention, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients admitted to ICU or Oncology units and identified to carry C. Difficile via VRE swab Exclusion Criteria: * Patients not identified as carriers of C. difficile and patients not admitted to ICU or oncology units
Where this trial is running
Boston, Massachusetts
- Brigham and Women's Hospital — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Meghan A Baker, MD, SCD — Brigham and Women's Hospital
- Study coordinator: Meghan A Baker, MD, SCD
- Email: mbaker1@bwh.harvard.edu
- Phone: 617-732-8881
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.